As you know, several less invasive treatment strategies have been explored to reduce toxicity. However, no clear advantage in terms of adverse events without compromising efficacy has been reported to date. Our study supports the current standard treatment, which included approximately 50 Gy of prophylactic radiation, such as SIB56 in definitive chemoradiation IMRT, demonstrating sufficient efficacy...
As you know, several less invasive treatment strategies have been explored to reduce toxicity. However, no clear advantage in terms of adverse events without compromising efficacy has been reported to date. Our study supports the current standard treatment, which included approximately 50 Gy of prophylactic radiation, such as SIB56 in definitive chemoradiation IMRT, demonstrating sufficient efficacy. Less invasive treatment approaches should be evaluated in well-designed clinical trials with appropriate patient selection based on recurrence risk.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
